MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Veracyte Company Profile (NASDAQ:VCYT)

Consensus Ratings for Veracyte (NASDAQ:VCYT) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.20 (101.98% upside)

Analysts' Ratings History for Veracyte (NASDAQ:VCYT)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Cantor FitzgeraldReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016BTIG ResearchReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2015StephensReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/14/2015Cowen and CompanyLower Price TargetOutperform$12.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015Piper JaffrayReiterated RatingOverweight$13.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2015William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2015Morgan StanleyReiterated RatingEqual Weight$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/14/2014Janney Montgomery ScottDowngradeBuy -> Neutral$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Veracyte (NASDAQ:VCYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/5/2016Q116($0.35)($0.36)$13.08 million$13.55 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.30)($0.29)$14.45 million$14.04 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.33)($0.32)$12.72 million$12.33 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.31)($0.35)$12.23 million$11.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.37)($0.34)$10.83 million$11.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015Q414($0.33)($0.36)$11.83 million$12.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.35)($0.37)$9.67 million$9.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.33)($0.31)$9.36 million$8.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.31)($0.32)$7.19 million$7.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2014Q4($0.38)($0.42)$6.43 million$6.84 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/25/2013Q313($6.59)$3.20 million$5.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Veracyte (NASDAQ:VCYT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.31)($0.31)($0.31)
Q2 20161($0.28)($0.28)($0.28)
Q3 20161($0.29)($0.29)($0.29)
Q4 20161($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)
Dividend History for Veracyte (NASDAQ:VCYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Veracyte (NASDAQ:VCYT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Bonnie H AndersonCEOBuy5,000$5.40$27,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Bonnie H AndersonCEOBuy5,000$5.46$27,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Bonnie H AndersonCEOBuy2,500$5.46$13,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Evan/ Fa JonesDirectorSell7,896$7.23$57,088.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Evan/ Fa JonesDirectorSell7,104$7.20$51,148.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2015Christopher M HallCOOSell2,500$11.85$29,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Shelly D GuyerCFOSell1,000$12.08$12,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Christopher M HallInsiderSell1,000$12.29$12,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Evan/ Fa JonesDirectorSell27,304$12.60$344,030.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Christopher M HallInsiderSell1,000$12.92$12,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2014Julie BrooksEVPBuy1,122$14.69$16,482.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/28/2014Julie BrooksEVPBuy1,000$14.71$14,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Julie BrooksVPBuy2,000$14.18$28,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2014Julie BrooksVPBuy1,000$14.00$14,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Christopher M HallInsiderSell3,000$14.92$44,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2014Bonnie H AndersonCEOSell1,000$17.95$17,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Bonnie H AndersonCEOSell4,000$16.45$65,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Christopher M HallInsiderSell2,000$16.95$33,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Shelly D GuyerCFOSell1,250$16.04$20,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Christopher M HallInsiderSell3,000$14.99$44,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2014Evan/ Fa JonesDirectorSell16,650$15.07$250,915.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Evan/ Fa JonesDirectorSell22,870$14.57$333,215.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2014Evan/ Fa JonesDirectorSell28,248$14.33$404,793.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2014Evan/ Fa JonesDirectorSell23,882$15.33$366,111.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Veracyte (NASDAQ:VCYT)
DateHeadline
06/20/16 04:49 PMVeracyte Now In Position For A Rate Increase In 2018 - Cantor Fitzgerald analyst Bryan Brokmeier told investors to buy shares of Veracyte Inc (NASDAQ: VCYT). "The shift to market-based pricing and clarity on the implementation timeline improves transparency and recognizes the value innovative tests bring to the market," Brokmeier said. Specifically related to Veracyte, the Cantor analyst noted "the final rule positions it to receive a rate increase in 2018. VCYT has been successful ...Full story available on Benzinga.com
06/17/16 06:19 PMVeracyte Releases Statement on CMS's Final PAMA Rule - [at noodls] - ce21e92b-c9f4-4fbc-ba75-bd44f5e01911.pdf June 17, 2016 Company Supports Agency's Plan to Bring Market-Based Medicare Pricing to Advanced Genomic Tests SOUTH SAN FRANCISCO, Calif., June 17, 2016 /PRNewswire/ ...
06/15/16 06:29 AMNotable Tuesday Option Activity: CCOI, SWHC, VCYT
06/13/16 03:19 PMVeracyte Announces Resignation of Its Chief Financial Officer - [at noodls] - 166a0869-be30-48f6-8798-f52ae4759941.pdf June 13, 2016 SOUTH SAN FRANCISCO, Calif., June 13, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of ...
06/10/16 09:09 PMVeracyte Statement on CMS's Preliminary Gapfill Rate for the Afirma® Gene Expression Classifier - [at noodls] - 881722d4-bcdc-4f02-8c4d-5c41fed019b3.pdf June 10, 2016 SOUTH SAN FRANCISCO, Calif., June 10, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of ...
06/01/16 07:00 AMVeracyte to Present at the William Blair & Company 36th Annual Growth Stock Conference - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., June 1, 2016 /PRNewswire/ -- Veracyte, Inc . (NASDAQ: VCYT) today announced that Chris Hall, chief operating officer, will present at the William Blair & Company 36 th Annual ...
05/27/16 12:43 PMVeracyte (VCYT) to Present New Thyroid Cancer Diagnosis Data at AACE 2016 - StreetInsider.com - Veracyte (VCYT) to Present New Thyroid Cancer Diagnosis Data at AACE 2016StreetInsider.comVeracyte, Inc. (NASDAQ: VCYT) announced findings from two studies demonstrating the challenge of using large gene-mutation panels to help physicians determine next steps for patients whose thyroid nodules are not clearly benign or malignant following ...
05/27/16 12:43 PMBroker Roundup For Veracyte, Inc. (VCYT) - Share Trading News - Broker Roundup For Veracyte, Inc. (VCYT)Share Trading News11/26/2013 – William Blair began new coverage on Veracyte, Inc. giving the company a “outperform” rating. The share price of Veracyte, Inc. (VCYT) was up +2.96% during the last trading session, with a day high of 5.56. 38178 shares were traded on ...and more »
05/27/16 06:47 AMVeracyte Announces New Data that Advance Understanding of the Role of Gene Alterations In Thyroid Cancer Diagnosis - [at noodls] - 730451c3-9839-412b-91dc-605e0f6c4ebf.pdf May 27, 2016 -- Findings presented at the American Association of Clinical Endocrinologists (AACE) Meeting -- SOUTH SAN FRANCISCO, Calif., May 27, 2016 /PRNewswire/ ...
05/23/16 06:56 AMVeracyte Announces Data from Multiple Studies Advancing Scientific Understanding of Thyroid Cancer to Be Presented at AACE Congress - [at noodls] - 98ec658a-904e-4fb5-8913-6eca8860006b.pdf May 23, 2016 SOUTH SAN FRANCISCO, Calif., May 23, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular ...
05/17/16 04:32 PMNew Data Suggesting Veracyte's Percepta® Bronchial Genomic Classifier Can Reduce Unnecessary Invasive Procedures In Lung Cancer Diagnosis Presented at ATS 2016 - [at noodls] - 6fa5f335-9603-4c86-a8b6-b972274dc780.pdf May 17, 2016 -- Study published concurrently in BMC Pulmonary Medicine -- -- Three additional studies presented at ATS 2016 reinforce the genomic classifier's clinical ...
05/17/16 03:28 PMVeracyte, Inc. :VCYT-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/05/16 04:15 PMVeracyte reports 1Q loss -
05/05/16 03:21 PMVeracyte Announces First Quarter 2016 Financial Results - [at noodls] - 31678dd4-01dc-4891-b782-91daec7b0c81.pdf May 5, 2016 Revenue Increased 21% and Afirma® GEC Volume Grew 33%, Compared to Same Quarter in 2015 Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN ...
04/09/16 01:34 PMEarnings View for Veracyte, Inc. (NASDAQ:VCYT) - RiversideGazette.com - Earnings View for Veracyte, Inc. (NASDAQ:VCYT)RiversideGazette.comWall Street analysts have a current quarter EPS estimate of $-0.35 on shares of Veracyte, Inc. (NASDAQ:VCYT). Analysts and investors will be looking ahead to the next company earnings report which is scheduled to be released on or around 2016-05-12 for ...and more »
04/09/16 01:34 PMVeracyte, Inc. (VCYT) Updated Broker Price Targets - Share Trading News - Veracyte, Inc. (VCYT) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Veracyte, Inc. (VCYT). The latest reports which are currently in issue on Friday 8th of April state 4 analysts have a rating of “strong buy”, 3 analysts “buy”, 2 ...and more »
04/09/16 01:34 PMGhost Tree Capital buys $1.7 Million stake in Veracyte Inc (VCYT) - Everything HUDSON - Ghost Tree Capital buys $1.7 Million stake in Veracyte Inc (VCYT)Everything HUDSONVeracyte Inc (VCYT) : Ghost Tree Capital scooped up 147,200 additional shares in Veracyte Inc during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 350,000 shares of Veracyte Inc which is ...Veracyte Inc Could Burn Your Portfolio. The Stock Formed Bearish Double BottomBusiness Standard Tribuneall 2 news articles »
04/09/16 01:34 PMPiper Jaffray Exits Position in Veracyte Inc (VCYT) - Street Edition - Piper Jaffray Exits Position in Veracyte Inc (VCYT)Street EditionVeracyte Inc (VCYT) : Piper Jaffray has sold out all of its stake in Veracyte Inc during the Q4 period, according to the information disclosed to the SEC. The investment management company has sold out 10,000 shares of Veracyte Inc which is valued at ...Recently Changed Price Targets On Veracyte, Inc. (VCYT)Risers & Fallersall 1 news articles »
04/02/16 12:28 PMClinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016 - [at noodls] - b86ba7e4-01a8-4ef3-89c9-f56f654201cc.pdf April 2, 2016 -- Study Advancing Genomic-Level Understanding of Hürthle Lesions Also Presented -- SOUTH SAN FRANCISCO, Calif., April 2, 2016 /PRNewswire/ -- Veracyte, ...
03/30/16 04:08 PMVERACYTE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sh -
03/29/16 03:24 PMMultiple Studies Showcasing Clinical Utility of Veracyte's Afirma® Gene Expression Classifier to Be Presented at ENDO 2016 - [at noodls] - 903869dc-840e-4a3f-a83b-9ac33cbead8e.pdf March 29, 2016 SOUTH SAN FRANCISCO, Calif., March 29, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that company and external researchers will ...
03/16/16 06:30 AMNew Data Show That Veracyte's Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., March 16, 2016 /PRNewswire/ -- Veracyte, Inc. (VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced publication of data demonstrating that the Afirma Gene Expression Classifier (GEC) reduces unnecessary surgeries in thyroid cancer diagnosis during long-term clinical follow-up. The study is the first to use a national healthcare claims database to determine the real-world impact of the genomic test on patient care and to quantify the costs associated with thyroid surgery. The Afirma GEC is used to identify patients whose thyroid nodules are benign, among those deemed indeterminate following traditional cytopathology evaluation, so that they may avoid diagnostic surgery.
03/14/16 03:26 PMVERACYTE, INC. Files SEC form 10-K, Annual Report -
03/14/16 11:37 AMVeracyte, Inc. :VCYT-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/14/16 09:34 AMThe Earnings Expectations From Veracyte, Inc. (NASDAQ:VCYT) - Investor Newswire - The Earnings Expectations From Veracyte, Inc. (NASDAQ:VCYT)Investor NewswireZacks uses two distinct mechanisms to assign a rating on any stock. One of the most frequently applied methods is to conduct the opinion poll of Wall Street analysts and then obtain an average rating. Following the last poll, Veracyte, Inc. (NASDAQ ...and more »
03/10/16 11:23 PMEdited Transcript of VCYT earnings conference call or presentation 10-Mar-16 9:30pm GMT -
03/10/16 05:27 PMVeracyte reports 4Q loss -
03/10/16 03:20 PMVERACYTE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/10/16 03:05 PMVeracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., March 10, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced financial results and business progress for the quarter and full year ended December 31, 2015, ...
03/10/16 06:07 AMQ4 2015 Veracyte Inc Earnings Release - After Market Close -
03/04/16 03:18 PMVERACYTE, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
02/29/16 03:05 PMVeracyte Announces Publication of Data Confirming Analytical Verification of Percepta® Bronchial Genomic Classifier - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 /PRNewswire/ -- Veracyte, Inc. (VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that data confirming the analytical performance of the company's Percepta Bronchial Genomic Classifier have been published online in the journal BMC Cancer. The findings add to the growing body of evidence, including previously reported clinical validity and clinical utility data, supporting the use of the Percepta classifier to help resolve ambiguity in lung cancer diagnosis and thus reduce the unnecessary, invasive procedures that can result. "The analytical verification data published today reinforce the quality and scientific rigor behind our Percepta Bronchial Genomic Classifier," said Bonnie Anderson, Veracyte's president and chief executive officer.
02/25/16 10:11 AMVeracyte Announces Publication of Data Supporting Clinical Utility of the Percepta® Bronchial Genomic Classifier in Lung Cancer Diagnosis - [PR Newswire] - Utilizing data from two prospective, multicenter studies,1,2 researchers determined that use of the Percepta classifier could have decreased unnecessary, invasive procedures in 50 percent of the evaluated patient population. The study analyzed patients with lung nodules or lesions whose bronchoscopy results were inconclusive for cancer and who were considered to have an intermediate or low risk of cancer prior to use of the Percepta classifier.
02/25/16 07:00 AMVeracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2015 Financial Results on March 10 - [PR Newswire] - Following the announcement, Veracyte's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and business progress. The live webcast and subsequent replay of the earnings call may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The conference ID number is 49854042.
02/19/16 06:30 AMVeracyte Announces Publication of Study Reinforcing the Clinical Utility of the Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., Feb. 19, 2016 /PRNewswire/ -- Veracyte, Inc. (VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that an independent clinical utility study reinforcing the ability of the Afirma Gene Expression Classifier (GEC) to significantly reduce unnecessary surgeries in thyroid cancer diagnosis was published in the February issue of Cancer Cytopathology. Researchers from the David Geffen School of Medicine at the University of California at Los Angeles evaluated all thyroid nodule fine needle aspirations (FNAs) performed during a 20-month period following introduction of the Afirma GEC at the institution to determine its impact on clinical practice. The genomic test is used when patients' thyroid nodule FNA results are deemed inconclusive by traditional cytopathology and helps identify patients whose thyroid nodules are actually benign – and who can thus safely avoid unnecessary diagnostic surgery.
02/15/16 01:24 PM13G Filing: Acuta Capital Partners Files on Veracyte, Inc. (VCYT) -
01/29/16 11:00 AMVeracyte (VCYT) Approved to Offer Percepta Bronchial Genomic Classifier for Patients in New York State - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has received regulatory authorization ...
01/28/16 07:12 AMVeracyte Receives Regulatory Authorization to Offer Percepta™ Bronchial Genomic Classifier for Patients in New York State - [at noodls] - 08e62458-aed5-49e9-b843-d0cba4450da7.pdf January 28, 2016 -- Genomic Test Helps Resolve Ambiguity in Lung Cancer Diagnosis -- SOUTH SAN FRANCISCO, Calif., Jan. 28, 2016 /PRNewswire/ --Â Veracyte, Inc. ...
01/27/16 07:26 AMVeracyte to Participate in Two Upcoming Investor Conferences - [at noodls] - a2436661-720d-492f-a814-c2443df4b899.pdf January 27, 2016 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2016 /PRNewswire/ --Â Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and ...
01/25/16 03:47 PMTuality's advanced lung cancer test could lead to the end of biopsies -
01/22/16 07:03 AMVeracyte Announces Publication of Long-Term Clinical Utility Study for the Afirma® Gene Expression Classifier - [at noodls] - 27f3f49d-cba8-43b9-a083-a329d41ca4e2.pdf January 22, 2016 SOUTH SAN FRANCISCO, Calif., Jan. 22, 2016 /PRNewswire/ --Â Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field ...
01/22/16 06:33 AM7:33 am Veracyte: Data demonstrating the ability of the Afirma Gene Expression Classifier to reduce thyroid surgeries during 3 years of follow-up were published online in Endocrine Practice -
01/07/16 03:40 PMVeracyte Announces Expansion to New South San Francisco Facility - [at noodls] - 3dc8d0c4-9511-4958-b347-a36e681c8ec7.pdf January 7, 2016 -- Move accommodates strong growth as company expands its genomic test offerings -- SOUTH SAN FRANCISCO, Calif., Jan. 7, 2016 /PRNewswire/ -- Veracyte, ...
12/23/15 08:31 AMVeracyte, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/21/15 07:00 AMVeracyte to Present at the 34th Annual J.P. Morgan Healthcare Conference - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2015 /PRNewswire/ -- Veracyte, Inc . (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the 34 th Annual ...
12/18/15 04:48 AMCoverage initiated on Veracyte by Cantor Fitzgerald -
12/14/15 03:29 PMVeracyte Announces Positive Coverage Policy for the Afirma® Gene Expression Classifier from Health Care Service Corporation (HCSC) - [at noodls] - 4cb06fd9-ac03-447d-a5f1-3a096a609f30.pdf December 14, 2015 -- Additional Blues Plan Issues Positive Coverage Decision for the Afirma GEC; Two More Sign In- Network Contracts -- SOUTH SAN FRANCISCO, Calif., ...
12/08/15 12:17 PMVERACYTE, INC. Financials -
11/24/15 03:13 PMVERACYTE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
11/18/15 03:29 PMMedical test makers win higher rates from feds, stocks rebound -
About Veracyte

Veracyte logoVeracyte, Inc. is a molecular diagnostics company. The Company is engaged in the field of molecular cytology providing genomic solutions to resolve diagnostic ambiguity and enable physicians to make treatment decisions at an early stage in patient care. It targets diseases in which a large number of patients undergo invasive diagnostic procedures that could be avoided with a diagnosis from a cytology sample. The Company's commercial solution, the Afirma Thyroid FNA Analysis, includes as its centerpiece the Gene Expression Classifier (GEC). The GEC allows physicians reduce the number of surgeries by employing a 142-gene signature to pre-operatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The offering also includes cytopathology testing and the Afirma Malignancy Classifiers. The Company markets and sells Afrma through a co-promotion agreement with Genzyme Corporation, a subsidiary of Sanofi.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VCYT
  • CUSIP:
Key Metrics:
  • Previous Close: $5.25
  • 50 Day Moving Average: $5.30
  • 200 Day Moving Average: $5.83
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $140.68M
  • Current Quarter EPS Consensus Estimate: $-1.31 EPS
Additional Links:
Veracyte (NASDAQ:VCYT) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha